{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:00:30Z","timestamp":1790200830230,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,2,11]],"date-time":"2016-02-11T00:00:00Z","timestamp":1455148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,2,11]],"date-time":"2016-02-11T00:00:00Z","timestamp":1455148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The treatment of breast cancer-induced osteolysis remains a challenge in clinical settings. Here, we explored the effect and mechanism of combined treatment with zoledronic acid (ZA) and plumbagin (PL), a widely investigated component derived from<jats:italic>Plumbago zeylanica<\/jats:italic>, against breast cancer-induced osteoclastogenesis. We found that the combined treatment with PL and ZA suppressed cell viability of precursor osteoclasts and synergistically inhibited MDA-MB-231-induced osteoclast formation (combination index=0.28) with the abrogation of recombinant mouse receptor activator of nuclear factor-<jats:italic>\u03ba<\/jats:italic>B ligand (RANKL)-induced activation of NF-<jats:italic>\u03ba<\/jats:italic>B\/MAPK (nuclear factor-<jats:italic>\u03ba<\/jats:italic>B\/mitogen-activated protein kinase) pathways. Molecular docking suggested a putative binding area within c-Jun N-terminal kinase\/extracellular signal-regulated kinase (JNK\/Erk) protease active sites through the structural mimicking of adenosine phosphate (ANP) by the spatial combination of PL with ZA. A homogeneous time-resolved fluorescence assay further illustrated the direct competitiveness of the dual drugs against ANP docking to phosphorylated JNK\/Erk, contributing to the inhibited downstream expression of c-Jun\/c-Fos\/NFATc-1 (nuclear factor of activated T cells, cytoplasmic, calcineurin-dependent 1). Then,<jats:italic>in vivo<\/jats:italic>testing demonstrated that the combined administration of PL and ZA attenuated breast cancer growth in the bone microenvironment. Additionally, these molecules prevented the destruction of proximal tibia, with significant reduction of tartrate-resistant acid phosphatase (TRAcP)-positive osteoclast cells and potentiation of apoptotic cancer cells, to a greater extent when combined than when the drugs were applied independently. Altogether, the combination treatment with PL and ZA could significantly and synergistically suppress osteoclastogenesis and inhibit tumorigenesis both<jats:italic>in vitro<\/jats:italic>and<jats:italic>in vivo<\/jats:italic>by simulating the spatial structure of ANP to inhibit competitively phosphorylation of c-Jun N-terminal kinase\/extracellular signal-regulated kinase (JNK\/Erk).<\/jats:p>","DOI":"10.1038\/cddis.2016.11","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T01:23:33Z","timestamp":1455240213000},"page":"e2094-e2094","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK\/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model"],"prefix":"10.1038","volume":"7","author":[{"given":"H","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T-y","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z-f","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X-g","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X-q","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y-g","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q-m","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T-t","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,11]]},"reference":[{"key":"BFcddis201611_CR1","doi-asserted-by":"publisher","first-page":"e1823","DOI":"10.1038\/cddis.2015.192","volume":"6","author":"A De Cola","year":"2015","unstructured":"De Cola A, Volpe S, Budani MC, Ferracin M, Lattanzio R, Turdo A et al. miR-205-5p-mediated downregulation of ErbB\/HER receptors in breast cancer stem cells results in targeted therapy resistance. Cell Death Dis 2015; 6: e1823.","journal-title":"Cell Death Dis"},{"key":"BFcddis201611_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4248\/BR201304007","volume":"1","author":"W Yan","year":"2013","unstructured":"Yan W, Tu B, Liu Y-y, Wang T-y, Qiao H, Zhai Z-j et al. Suppressive effects of plumbagin on invasion and migration of breast cancer cells via the inhibition of STAT3 signaling and down-regulation of inflammatory cytokine expressions. Bone Res 2013; 1: 362\u2013370.","journal-title":"Bone Res"},{"key":"BFcddis201611_CR3","doi-asserted-by":"publisher","first-page":"e78043","DOI":"10.1371\/journal.pone.0078043","volume":"8","author":"T Rana","year":"2013","unstructured":"Rana T, Chakrabarti A, Freeman M, Biswas S . Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGFbeta. PLoS One 2013; 8: e78043.","journal-title":"PLoS One"},{"key":"BFcddis201611_CR4","first-page":"931","volume":"93","author":"AA Rose","year":"2006","unstructured":"Rose AA, Siegel PM . Breast cancer-derived factors facilitate osteolytic bone metastasis. Bull Cancer 2006; 93: 931\u2013943.","journal-title":"Bull Cancer"},{"key":"BFcddis201611_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1146\/annurev-pathol-011110-130203","volume":"6","author":"X Feng","year":"2011","unstructured":"Feng X, McDonald JM . Disorders of bone remodeling. Annu Rev Pathol 2011; 6: 121\u2013145.","journal-title":"Annu Rev Pathol"},{"key":"BFcddis201611_CR6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1634\/theoncologist.11-10-1121","volume":"11","author":"TA Guise","year":"2006","unstructured":"Guise TA . Bone loss and fracture risk associated with cancer therapy. Oncologist 2006; 11: 1121\u20131131.","journal-title":"Oncologist"},{"key":"BFcddis201611_CR7","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1111\/j.1582-4934.2012.01527.x","volume":"16","author":"L Insalaco","year":"2012","unstructured":"Insalaco L, Di Gaudio F, Terrasi M, Amodeo V, Caruso S, Corsini LR et al. Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells. J Cell Mol Med 2012; 16: 2186\u20132195.","journal-title":"J Cell Mol Med"},{"key":"BFcddis201611_CR8","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","volume":"84","author":"SP Jagdev","year":"2001","unstructured":"Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI . The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J cancer 2001; 84: 1126\u20131134.","journal-title":"Br J cancer"},{"key":"BFcddis201611_CR9","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1359\/jbmr.2000.15.11.2211","volume":"15","author":"O Fromigue","year":"2000","unstructured":"Fromigue O, Lagneaux L, Body JJ . Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000; 15: 2211\u20132221.","journal-title":"J Bone Miner Res"},{"key":"BFcddis201611_CR10","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrclinonc.2014.152","volume":"11","author":"A Mathew","year":"2014","unstructured":"Mathew A, Brufsky A . Breast cancer: zoledronic acid \u2013 more than just a bone drug. Nat Rev Clin Oncol 2014; 11: 564\u2013565.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFcddis201611_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/ijc.28965","volume":"137","author":"A Mathew","year":"2014","unstructured":"Mathew A, Brufsky A . Bisphosphonates in breast cancer. Int J Cancer 2014; 137: 753\u2013764.","journal-title":"Int J Cancer"},{"key":"BFcddis201611_CR12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3892\/ijo.2013.1809","volume":"42","author":"T Ibrahim","year":"2013","unstructured":"Ibrahim T, Liverani C, Mercatali L, Sacanna E, Zanoni M, Fabbri F et al. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines. Int J Oncol 2013; 42: 1263\u20131270.","journal-title":"Int J Oncol"},{"key":"BFcddis201611_CR13","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00432-014-1882-1","volume":"141","author":"KW Luo","year":"2014","unstructured":"Luo KW, Ko CH, Yue GG, Gao S, Lee JK, Li G et al. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model. J Cancer Res Clin Oncol 2014; 141: 1025\u20131036.","journal-title":"J Cancer Res Clin Oncol"},{"key":"BFcddis201611_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/sj.bjc.6603548","volume":"96","author":"N Horie","year":"2007","unstructured":"Horie N, Murata H, Kimura S, Takeshita H, Sakabe T, Matsui T et al. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. Br J cancer 2007; 96: 255\u2013261.","journal-title":"Br J cancer"},{"key":"BFcddis201611_CR15","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/aps.2015.42","volume":"36","author":"H Qiao","year":"2015","unstructured":"Qiao H, Wang TY, Yan W, Qin A, Fan QM, Han XG et al. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid in vitro. Acta Pharmacol Sin 2015; 36: 1085\u20131098.","journal-title":"Acta Pharmacol Sin"},{"key":"BFcddis201611_CR16","doi-asserted-by":"publisher","first-page":"10137","DOI":"10.1073\/pnas.0403621101","volume":"101","author":"DK Biswas","year":"2004","unstructured":"Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB et al. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 2004; 101: 10137\u201310142.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis201611_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10549-014-2844-7","volume":"144","author":"Z Zhai","year":"2014","unstructured":"Zhai Z, Qu X, Yan W, Li H, Liu G, Liu X et al. Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling. Breast Cancer Res Treat 2014; 144: 33\u201345.","journal-title":"Breast Cancer Res Treat"},{"key":"BFcddis201611_CR18","doi-asserted-by":"crossref","first-page":"22918","DOI":"10.18632\/oncotarget.4382","volume":"6","author":"L Zhang","year":"2015","unstructured":"Zhang L, Teng Y, Fan Y, Wang Y, Li W, Shi J et al. The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis. Oncotarget 2015; 6: 22918\u201322933.","journal-title":"Oncotarget"},{"key":"BFcddis201611_CR19","first-page":"14432","volume":"8","author":"CH Yan","year":"2015","unstructured":"Yan CH, Li F, Ma YC . Plumbagin shows anticancer activity in human osteosarcoma (MG-63) cells via the inhibition of S-phase checkpoints and down-regulation of c-myc. Int J Clin Exp Med 2015; 8: 14432\u201314439.","journal-title":"Int J Clin Exp Med"},{"key":"BFcddis201611_CR20","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ejphar.2015.08.058","volume":"765","author":"GH Hwang","year":"2015","unstructured":"Hwang GH, Ryu JM, Jeon YJ, Choi J, Han HJ, Lee YM et al. The role of thioredoxin reductase and glutathione reductase in plumbagin-induced, reactive oxygen species-mediated apoptosis in cancer cell lines. Eur J Pharmacol 2015; 765: 384\u2013393.","journal-title":"Eur J Pharmacol"},{"key":"BFcddis201611_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.mrgentox.2015.06.004","volume":"793","author":"AK Khaw","year":"2015","unstructured":"Khaw AK, Sameni S, Venkatesan S, Kalthur G, Hande MP . Plumbagin alters telomere dynamics, induces DNA damage and cell death in human brain tumour cells. Mutat Res Genet Toxicol Environ Mutagen 2015; 793: 86\u201395.","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"BFcddis201611_CR22","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.2147\/DDDT.S75976","volume":"9","author":"ZW Zhou","year":"2015","unstructured":"Zhou ZW, Li XX, He ZX, Pan ST, Yang Y, Zhang X et al. Induction of apoptosis and autophagy via sirtuin1- and PI3K\/Akt\/mTOR-mediated pathways by plumbagin in human prostate cancer cells. Drug Des Dev Ther 2015; 9: 1511\u20131554.","journal-title":"Drug Des Dev Ther"},{"key":"BFcddis201611_CR23","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1111\/febs.12429","volume":"280","author":"A Bhattacharya","year":"2013","unstructured":"Bhattacharya A, Jindal B, Singh P, Datta A, Panda D . Plumbagin inhibits cytokinesis in Bacillus subtilis by inhibiting FtsZ assembly \u2013 a mechanistic study of its antibacterial activity. FEBS J 2013; 280: 4585\u20134599.","journal-title":"FEBS J"},{"key":"BFcddis201611_CR24","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.intimp.2009.03.022","volume":"9","author":"R Checker","year":"2009","unstructured":"Checker R, Sharma D, Sandur SK, Khanam S, Poduval TB . Anti-inflammatory effects of plumbagin are mediated by inhibition of NF-kappaB activation in lymphocytes. Int Immunopharmacol 2009; 9: 949\u2013958.","journal-title":"Int Immunopharmacol"},{"key":"BFcddis201611_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1472-6882-14-15","volume":"14","author":"W Sumsakul","year":"2014","unstructured":"Sumsakul W, Plengsuriyakarn T, Chaijaroenkul W, Viyanant V, Karbwang J, Na-Bangchang K . Antimalarial activity of plumbagin in vitro and in animal models. BMC Complement Altern Med 2014; 14: 15.","journal-title":"BMC Complement Altern Med"},{"key":"BFcddis201611_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1211\/0022357055119","volume":"57","author":"Y Ding","year":"2005","unstructured":"Ding Y, Chen ZJ, Liu S, Che D, Vetter M, Chang CH . Inhibition of Nox-4 activity by plumbagin, a plant-derived bioactive naphthoquinone. J Pharm Pharmacol 2005; 57: 111\u2013116.","journal-title":"J Pharm Pharmacol"},{"key":"BFcddis201611_CR27","doi-asserted-by":"publisher","first-page":"7164","DOI":"10.1016\/j.biomaterials.2012.06.026","volume":"33","author":"Sl Thamake","year":"2012","unstructured":"Thamake Sl, Raul SL, Gryczynski Z, Ranjan AP, Vishwanatha J . Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials 2012; 33: 7164\u20137173.","journal-title":"Biomaterials"},{"key":"BFcddis201611_CR28","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1517\/17425247.2015.1021679","volume":"12","author":"DA Ossipov","year":"2015","unstructured":"Ossipov DA . Bisphosphonate-modified biomaterials for drug delivery and bone tissue engineering. Expert Opin Drug Deliv 2015; 12: 1443\u20131458.","journal-title":"Expert Opin Drug Deliv"},{"key":"BFcddis201611_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/1061186X.2014.950668","volume":"23","author":"T Singh","year":"2015","unstructured":"Singh T, Kaur V, Kumar M, Kaur P, Murthy RS, Rawal RK . The critical role of bisphosphonates to target bone cancer metastasis: an overview. J Drug Target 2015; 23: 1\u201315.","journal-title":"J Drug Target"},{"key":"BFcddis201611_CR30","first-page":"1634","volume":"73","author":"K Menuki","year":"2015","unstructured":"Menuki K, Sakai A . Pharmacology of bone resorption inhibitor. Nihon Rinsho Jpn J Clin Med 2015; 73: 1634\u20131638.","journal-title":"Nihon Rinsho Jpn J Clin Med"},{"key":"BFcddis201611_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1196\/annals.1365.036","volume":"1092","author":"I Lambrinoudaki","year":"2006","unstructured":"Lambrinoudaki I, Christodoulakos G, Botsis D . Bisphosphonates. Ann NY Acad Sci 2006; 1092: 397\u2013402.","journal-title":"Ann NY Acad Sci"},{"key":"BFcddis201611_CR32","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s00776-014-0557-8","volume":"19","author":"DK Khajuria","year":"2014","unstructured":"Khajuria DK, Razdan R, Mahapatra DR . Zoledronic acid in combination with alfacalcidol has additive effects on trabecular microarchitecture and mechanical properties in osteopenic ovariectomized rats. J Orthop Sci 2014; 19: 646\u2013656.","journal-title":"J Orthop Sci"},{"key":"BFcddis201611_CR33","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/abbs\/gmu069","volume":"46","author":"Y Yu","year":"2014","unstructured":"Yu Y, Song Z, Yang S, Yang X, Zhang J, Lu S . Everolimus and zoledronic acid\u2014a potential synergistic treatment for lung adenocarcinoma bone metastasis. Acta Biochim Biophys Sin 2014; 46: 792\u2013801.","journal-title":"Acta Biochim Biophys Sin"},{"key":"BFcddis201611_CR34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0167-5699(00)01718-7","volume":"21","author":"YY Kong","year":"2000","unstructured":"Kong YY, Boyle WJ, Penninger JM . Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today 2000; 21: 495\u2013502.","journal-title":"Immunol Today"},{"key":"BFcddis201611_CR35","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL . Osteoclast differentiation and activation. Nature 2003; 423: 337\u2013342.","journal-title":"Nature"},{"key":"BFcddis201611_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2008.10.146","volume":"378","author":"NS Soysa","year":"2009","unstructured":"Soysa NS, Alles N . NF-kappaB functions in osteoclasts. Biochem Biophys Res Commun 2009; 378: 1\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFcddis201611_CR37","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/j.1399-0004.2010.01619.x","volume":"80","author":"DA Stevenson","year":"2011","unstructured":"Stevenson DA, Schwarz EL, Carey JC, Viskochil DH, Hanson H, Bauer S et al. Bone resorption in syndromes of the Ras\/MAPK pathway. Clin Genet 2011; 80: 566\u2013573.","journal-title":"Clin Genet"},{"key":"BFcddis201611_CR38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/15216540500137669","volume":"57","author":"X Feng","year":"2005","unstructured":"Feng X . RANKing intracellular signaling in osteoclasts. IUBMB Life 2005; 57: 389\u2013395.","journal-title":"IUBMB Life"},{"key":"BFcddis201611_CR39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/jcb.22800","volume":"112","author":"E Ang","year":"2011","unstructured":"Ang E, Liu Q, Qi M, Liu HG, Yang X, Chen H et al. Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL-induced activation of NF-kappaB and ERK. J Cell Biochem 2011; 112: 89\u201397.","journal-title":"J Cell Biochem"},{"key":"BFcddis201611_CR40","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1124\/mol.107.034173","volume":"72","author":"HJ Kim","year":"2007","unstructured":"Kim HJ, Lee Y, Chang EJ, Kim HM, Hong SP, Lee ZH et al. Suppression of osteoclastogenesis by N,N-dimethyl-d-erythro-sphingosine: a sphingosine kinase inhibition-independent action. Mol Pharmacol 2007; 72: 418\u2013428.","journal-title":"Mol Pharmacol"},{"key":"BFcddis201611_CR41","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1172\/JCI200419657","volume":"114","author":"F Ikeda","year":"2004","unstructured":"Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 2004; 114: 475\u2013484.","journal-title":"J Clin Invest"},{"key":"BFcddis201611_CR42","doi-asserted-by":"publisher","first-page":"31155","DOI":"10.1074\/jbc.M001229200","volume":"275","author":"M Matsumoto","year":"2000","unstructured":"Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M . Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 2000; 275: 31155\u201331161.","journal-title":"J Biol Chem"},{"key":"BFcddis201611_CR43","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.str.2015.06.027","volume":"23","author":"S Lu","year":"2015","unstructured":"Lu S, Deng R, Jiang H, Song H, Li S, Shen Q et al. The mechanism of ATP-dependent allosteric protection of Akt kinase phosphorylation. Structure (London, England: 1993) 2015; 23: 1725\u20131734.","journal-title":"Structure (London, England: 1993)"},{"key":"BFcddis201611_CR44","first-page":"1","volume":"10","author":"KN Klotz","year":"2015","unstructured":"Klotz KN, Kachler S . Inhibitors of membranous adenylyl cyclases with affinity for adenosine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 2015; 10: 1\u20134.","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"BFcddis201611_CR45","first-page":"1","volume":"10","author":"Z Liu","year":"2015","unstructured":"Liu Z, Bone N, Jiang S, Park DW, Tadie JM, Deshane J et al. AMP-activated protein kinase and glycogen synthase kinase 3beta modulate the severity of sepsis-induced lung injury. Mol Med (Cambridge, MA) 2015; 10: 1\u20135.","journal-title":"Mol Med (Cambridge, MA)"},{"key":"BFcddis201611_CR46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.bcp.2015.05.004","volume":"96","author":"D Schroder","year":"2015","unstructured":"Schroder D, Todter K, Gonzalez B, Franco-Echevarria E, Rohaly G, Blecher C et al. The new InsP3 kinase inhibitor BIP-4 is competitive to InsP3 and blocks proliferation and adhesion of lung cancer cells. Biochem Pharmacol 2015; 96: 143\u2013150.","journal-title":"Biochem Pharmacol"},{"key":"BFcddis201611_CR47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ardp.201000028","volume":"343","author":"M Rabiller","year":"2010","unstructured":"Rabiller M, Getlik M, Kluter S, Richters A, Tuckmantel S, Simard JR et al. Proteus in the world of proteins: conformational changes in protein kinases. Arch Pharm 2010; 343: 193\u2013206.","journal-title":"Arch Pharm"},{"key":"BFcddis201611_CR48","doi-asserted-by":"publisher","first-page":"13286","DOI":"10.1021\/ja902010p","volume":"131","author":"JR Simard","year":"2009","unstructured":"Simard JR, Getlik M, Grutter C, Pawar V, Wulfert S, Rabiller M et al. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. J Am Chem Soc 2009; 131: 13286\u201313296.","journal-title":"J Am Chem Soc"},{"key":"BFcddis201611_CR49","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1111\/ajt.12799","volume":"14","author":"BR Rosborough","year":"2014","unstructured":"Rosborough BR, Raich-Regue D, Liu Q, Venkataramanan R, Turnquist HR, Thomson AW . Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection. Am J Transplant 2014; 14: 2173\u20132180.","journal-title":"Am J Transplant"},{"key":"BFcddis201611_CR50","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s10495-014-1066-0","volume":"20","author":"H Zhang","year":"2015","unstructured":"Zhang H, Dou J, Yu Y, Zhao Y, Fan Y, Cheng J et al. mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling. Apoptosis 2015; 20: 50\u201362.","journal-title":"Apoptosis"},{"key":"BFcddis201611_CR51","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.cbi.2015.03.028","volume":"233","author":"TM Motawi","year":"2015","unstructured":"Motawi TM, Sadik NA, Fahim SA, Shouman SA . Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells. Chem Biol Interact 2015; 233: 147\u2013156.","journal-title":"Chem Biol Interact"},{"key":"BFcddis201611_CR52","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1099\/jmm.0.073890-0","volume":"63","author":"H Guo","year":"2014","unstructured":"Guo H, Xie SM, Li SX, Song YJ, Lv XL, Zhang H . Synergistic mechanism for tetrandrine on fluconazole against Candida albicans through the mitochondrial aerobic respiratory metabolism pathway. J Med Microbiol 2014; 63: 988\u2013996.","journal-title":"J Med Microbiol"},{"key":"BFcddis201611_CR53","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1124\/jpet.109.158329","volume":"331","author":"HR Hope","year":"2009","unstructured":"Hope HR, Anderson GD, Burnette BL, Compton RP, Devraj RV, Hirsch JL et al. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation. J Pharmacol Exp Ther 2009; 331: 882\u2013895.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFcddis201611_CR54","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/1535-7163.MCT-09-0745","volume":"8","author":"I Zinonos","year":"2009","unstructured":"Zinonos I, Labrinidis A, Lee M, Liapis V, Hay S, Ponomarev V et al. Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer. Mol Cancer Ther 2009; 8: 2969\u20132980.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis201611_CR55","first-page":"157","volume":"2","author":"HJWY Tong","year":"2014","unstructured":"Tong HJ WY, Yang F, Shi Q, Dai KR, Zhang XL . A novel in vitro system for intracellular delivery of nonviral DNA. J Orthop Transl 2014; 2: 157\u2013164.","journal-title":"J Orthop Transl"},{"key":"BFcddis201611_CR56","doi-asserted-by":"publisher","first-page":"10287","DOI":"10.1073\/pnas.1401337111","volume":"111","author":"A Swami","year":"2014","unstructured":"Swami A, Reagan MR, Basto P, Mishima Y, Kamaly N, Glavey S et al. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci USA 2014; 111: 10287\u201310292.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis201611_CR57","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1359\/jbmr.2001.16.8.1486","volume":"16","author":"T Yoneda","year":"2001","unstructured":"Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R . A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 2001; 16: 1486\u20131495.","journal-title":"J Bone Miner Res"},{"key":"BFcddis201611_CR58","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.fct.2013.11.027","volume":"64","author":"T Wang","year":"2014","unstructured":"Wang T, Wu F, Jin Z, Zhai Z, Wang Y, Tu B et al. Plumbagin inhibits LPS-induced inflammation through the inactivation of the nuclear factor-kappa B and mitogen activated protein kinase signaling pathways in RAW 264.7 cells. Food Chem Toxicol 2014; 64: 177\u2013183.","journal-title":"Food Chem Toxicol"},{"key":"BFcddis201611_CR59","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/aps.2013.152","volume":"35","author":"W Yan","year":"2014","unstructured":"Yan W, Wang TY, Fan QM, Du L, Xu JK, Zhai ZJ et al. Plumbagin attenuates cancer cell growth and osteoclast formation in the bone microenvironment of mice. Acta Pharmacol Sin 2014; 35: 124\u2013134.","journal-title":"Acta Pharmacol Sin"},{"key":"BFcddis201611_CR60","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1080\/10428190802353591","volume":"49","author":"TC Chou","year":"2008","unstructured":"Chou TC . Preclinical versus clinical drug combination studies. Leuk Lymph 2008; 49: 2059\u20132080.","journal-title":"Leuk Lymph"},{"key":"BFcddis201611_CR61","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27\u201355.","journal-title":"Adv Enzyme Regul"},{"key":"BFcddis201611_CR62","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1053\/j.gastro.2007.12.011","volume":"134","author":"TN Pham","year":"2008","unstructured":"Pham TN, King D, Macparland SA, McGrath JS, Reddy SB, Bursey FR et al. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology 2008; 134: 812\u2013822.","journal-title":"Gastroenterology"},{"key":"BFcddis201611_CR63","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.1128\/JVI.78.11.5867-5874.2004","volume":"78","author":"TN Pham","year":"2004","unstructured":"Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI . Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004; 78: 5867\u20135874.","journal-title":"J Virol"},{"key":"BFcddis201611_CR64","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH645>3.0.CO;2-Q","volume":"192","author":"TJ Chambers","year":"2000","unstructured":"Chambers TJ . Regulation of the differentiation and function of osteoclasts. J Pathol 2000; 192: 4\u201313.","journal-title":"J Pathol"},{"key":"BFcddis201611_CR65","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/sj.cdd.4401285","volume":"10","author":"H Glantschnig","year":"2003","unstructured":"Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA . M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR\/S6 kinase. Cell Death Differ 2003; 10: 1165\u20131177.","journal-title":"Cell Death Differ"},{"key":"BFcddis201611_CR66","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V","volume":"46","author":"ER Stanley","year":"1997","unstructured":"Stanley ER, Berg KL, Einstein DB, Lee PS, Pixley FJ, Wang Y et al. Biology and action of colony-stimulating factor-1. Mol Reprod Dev 1997; 46: 4\u201310.","journal-title":"Mol Reprod Dev"},{"key":"BFcddis201611_CR67","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ . AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010; 31: 455\u2013461.","journal-title":"J Comput Chem"},{"key":"BFcddis201611_CR68","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ab.2006.05.006","volume":"356","author":"Y Jia","year":"2006","unstructured":"Jia Y, Quinn CM, Gagnon AI, Talanian R . Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery. Anal Biochem 2006; 356: 273\u2013281.","journal-title":"Anal Biochem"},{"key":"BFcddis201611_CR69","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ab.2005.11.010","volume":"350","author":"Y Jia","year":"2006","unstructured":"Jia Y, Quinn CM, Clabbers A, Talanian R, Xu Y, Wishart N et al. Comparative analysis of various in vitro COT kinase assay formats and their applications in inhibitor identification and characterization. Anal Biochem 2006; 350: 268\u2013276.","journal-title":"Anal Biochem"},{"key":"BFcddis201611_CR70","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.abb.2005.06.020","volume":"441","author":"Y Jia","year":"2005","unstructured":"Jia Y, Quinn CM, Bump NJ, Clark KM, Clabbers A, Hardman J et al. Purification and kinetic characterization of recombinant human mitogen-activated protein kinase kinase kinase COT and the complexes with its cellular partner NF-kappa B1 p105. Arch Biochem Biophys 2005; 441: 64\u201374.","journal-title":"Arch Biochem Biophys"},{"key":"BFcddis201611_CR71","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.bone.2006.09.016","volume":"40","author":"Y Zheng","year":"2007","unstructured":"Zheng Y, Zhou H, Brennan K, Blair JM, Modzelewski JR, Seibel MJ et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 2007; 40: 471\u2013478.","journal-title":"Bone"},{"key":"BFcddis201611_CR72","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bone.2013.07.006","volume":"56","author":"X Bi","year":"2013","unstructured":"Bi X, Sterling JA, Merkel AR, Perrien DS, Nyman JS, Mahadevan-Jansen A . Prostate cancer metastases alter bone mineral and matrix composition independent of effects on bone architecture in mice \u2013 a quantitative study using microCT and Raman spectroscopy. Bone 2013; 56: 454\u2013460.","journal-title":"Bone"}],"updated-by":[{"DOI":"10.1038\/s41419-019-1606-1","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T00:00:00Z","timestamp":1557273600000},"record-id":"20424"},{"DOI":"10.1038\/s41419-019-1606-1","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T00:00:00Z","timestamp":1557273600000}}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cddis201611.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis201611","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis201611.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T09:20:47Z","timestamp":1718356847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis201611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,11]]},"references-count":72,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2]]}},"alternative-id":["BFcddis201611"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2016.11","relation":{"retraction":[{"id-type":"doi","id":"10.1038\/s41419-019-1606-1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,11]]},"assertion":[{"value":"25 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}